China Pacific Insurance (02601) announced that the net profit attributable to shareholders in 2025 is 53.505 billion yuan, an increase of 19.0% year-on-year.
China Pacific Insurance (Group) Co., Ltd. (02601) announced its performance for 2025, achieving a total operating income of RMB 435.156 billion, a year-on-year increase of 7.7%. Among which, insurance service income was RMB 288.91 billion, a year-on-year increase of 3.4%; the group's attributable net profit was RMB 53.505 billion, a year-on-year increase of 19.0%; the group's attributable operating profit was RMB 36.523 billion, a year-on-year increase of 6.1%. The income and profit levels maintained a steady growth trend.
China Pacific Insurance (02601) announced its performance in 2025, achieving total operating income of 435.156 billion yuan, a year-on-year growth of 7.7%. Among which, insurance service income reached 288.91 billion yuan, a year-on-year growth of 3.4%; group net profit attributable to shareholders was 53.505 billion yuan, a year-on-year growth of 19.0%; group operating profit attributable to shareholders was 36.523 billion yuan, a year-on-year growth of 6.1%. The revenue and profit levels maintained a steady growth trend. As of the end of 2025, the group's embedded value was 613.365 billion yuan, a 9.1% increase from the previous year; group net assets attributable to shareholders were 302.143 billion yuan, a 3.7% increase from the previous year; the group's management asset scale was 38.9 trillion yuan, a 9.8% increase from the previous year, showing a steady improvement in overall comprehensive strength.
Tai Bao Life Insurance's core operating performance remained steady and saw growth in scale and value, with profitability and business quality maintaining a good trend. In 2025, it achieved premium income of 295.855 billion yuan, a year-on-year growth of 12.7%. The embedded value reached 465.479 billion yuan, a 10.2% increase from the previous year; new business value reached 18.609 billion yuan, a year-on-year growth of 40.1%; new business value rate was 19.8%, a 3.2 percentage point increase from the previous year. Net profit was 42.165 billion yuan, a year-on-year growth of 17.7%; operating profit was 28.916 billion yuan, a year-on-year growth of 4.8%.
Pacific Health Insurance is targeting the strategic direction of "new products, new channels, new technologies" and continuously improving its professional operating capabilities. The development speed steadily increased, achieving insurance business income of 8.933 billion yuan in 2025, a year-on-year growth of 14.4%. The self-operated businesses such as the Internet and medical ecology and cooperation business with Tai Bao Life Insurance achieved good growth. The quality of development continued to improve, with insurance service income reaching 3.683 billion yuan in 2025 under the new accounting standards, a year-on-year growth of 39.7%; net profit was 260 million yuan, a year-on-year growth of 185.7%. As of the end of 2025, the company has achieved cumulative profitability, further enhancing its operational resilience.
In 2025, Tai Bao Property Insurance achieved original insurance premium income of 201.499 billion yuan, a year-on-year growth of 0.1%, insurance service income of 197.191 billion yuan, a year-on-year growth of 3.0%. It achieved underwriting profit of 4.836 billion yuan, a year-on-year growth of 81.0%. The underwriting combined ratio was 97.5%, a decrease of 1.1 percentage points from the previous year, with an underwriting combined loss ratio of 70.4%, a decrease of 0.4 percentage points, and an underwriting combined expense ratio of 27.1%, a decrease of 0.7 percentage points.
Related Articles

JS GLOBAL LIFE (01691): Huang Shuling resigns as executive director

JS Global Life (01691): Executive Director Han Run appointed as Chief Executive Officer.

ZHONGZHIPHARM (03737) announced that the profit attributable to equity holders in 2025 was RMB 17.29 million, a year-on-year decrease of 81.8%.
JS GLOBAL LIFE (01691): Huang Shuling resigns as executive director

JS Global Life (01691): Executive Director Han Run appointed as Chief Executive Officer.

ZHONGZHIPHARM (03737) announced that the profit attributable to equity holders in 2025 was RMB 17.29 million, a year-on-year decrease of 81.8%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


